Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2 AND Clinical Outcome
20 results:

  • 1. EPLIN, a Putative Tumour Suppressor in colorectal cancer, Implications in Drug Resistance.
    Zeng J; Sanders AJ; Ye L; Hargest R; Ruge F; Jiang WG
    Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499558
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. A Possible Distinct Molecular Subtype (Quintuple-Wildtype) of Metastatic colorectal cancer in First-Line Anti-EGFR Therapy with Cetuximab Plus FOLFIRI - Palliative Precision Therapy and a Multidisciplinary Treatment Approach: Interim Analysis of the IVOPAK II Trial with Early Results.
    Wein A; Stoehr R; Kersting S; Siebler J; Merkel S; Busse D; Wolff K; Ostermeier N; Neufert C; Vitali F; Eckstein M; Roth JP; Anhut P; Schreiner W; Uder M; Hartmann A; Neurath MF; Grützmann R
    Oncology; 2022; 100(1):1-11. PubMed ID: 34670215
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. ESR1, PGR, erbb2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6.
    Filipits M; Rudas M; Singer CF; Fitzal F; Bago-Horvath Z; Greil R; Balic M; Lax SF; Halper S; Hulla W; Wu NC; Liu X; Weidler J; Bates M; Hlauschek D; Gnant M; Dubsky P
    ESMO Open; 2021 Aug; 6(4):100228. PubMed ID: 34371382
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Long-term clinical outcome of Trastuzumab and Lapatinib for her2-positive Metastatic colorectal cancer.
    Tosi F; Sartore-Bianchi A; Lonardi S; Amatu A; Leone F; Ghezzi S; Martino C; Bencardino K; Bonazzina E; Bergamo F; Fenocchio E; Martinelli E; Troiani T; Siravegna G; Mauri G; Torri V; Marrapese G; Valtorta E; Cassingena A; Cappello G; Bonoldi E; Vanzulli A; Regge D; Ciardiello F; Zagonel V; Bardelli A; Trusolino L; Marsoni S; Siena S
    Clin Colorectal Cancer; 2020 Dec; 19(4):256-262.e2. PubMed ID: 32919890
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. HER4 promotes the progression of colorectal cancer by promoting epithelial‑mesenchymal transition.
    Jia X; Wang H; Li Z; Yan J; Guo Y; Zhao W; Gao L; Wang B; Jia Y
    Mol Med Rep; 2020 Apr; 21(4):1779-1788. PubMed ID: 32319604
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Depth of response predicts the clinical outcome of advanced her2-positive gastric cancer to trastuzumab-based first-line chemotherapy.
    Kadowaki S; Masuishi T; Eto T; Narita Y; Taniguchi H; Ura T; Ando M; Tajika M; Niwa Y; Yatabe Y; Muro K
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):807-813. PubMed ID: 28821938
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Pooled Analysis of clinical outcome of Patients with Chemorefractory Metastatic colorectal cancer Treated within Phase I/II clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience.
    Sartore-Bianchi A; Amatu A; Bonazzina E; Stabile S; Giannetta L; Cerea G; Schiavetto I; Bencardino K; Funaioli C; Ricotta R; Cipani T; Schirru M; Gambi V; Palmeri L; Carlo-Stella G; Rusconi F; Di Bella S; Burrafato G; Cassingena A; Valtorta E; Lauricella C; Pazzi F; Gambaro A; Ghezzi S; Marrapese G; Tarenzi E; Veronese S; Truini M; Vanzulli A; Siena S
    Target Oncol; 2017 Aug; 12(4):525-533. PubMed ID: 28669023
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Rationally co-targeting divergent pathways in KRAS wild-type colorectal cancers by CANscript technology reveals tumor dependence on Notch and erbb2.
    Brijwani N; Jain M; Dhandapani M; Zahed F; Mukhopadhyay P; Biswas M; Khatri D; Radhakrishna VD; Majumder B; Radhakrishnan P; Thiyagarajan S
    Sci Rep; 2017 May; 7(1):1502. PubMed ID: 28473715
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. ErbB-3 activation by NRG-1β sustains growth and promotes vemurafenib resistance in BRAF-V600E colon cancer stem cells (CSCs).
    Prasetyanti PR; Capone E; Barcaroli D; D'Agostino D; Volpe S; Benfante A; van Hooff S; Iacobelli V; Rossi C; Iacobelli S; Medema JP; De Laurenzi V; Sala G
    Oncotarget; 2015 Jul; 6(19):16902-11. PubMed ID: 26160848
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. HER3 expression in primary colorectal cancer including corresponding metastases in lymph node and liver.
    Lédel F; Stenstedt K; Hallström M; Ragnhammar P; Edler D
    Acta Oncol; 2015 Apr; 54(4):480-6. PubMed ID: 25601452
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Beyond RAS: the role of epidermal growth factor receptor (EGFR) and its network in the prediction of clinical outcome during anti-EGFR treatment in colorectal cancer patients.
    Giampieri R; Aprile G; Del Prete M; Faloppi L; Bianconi M; Bonotto M; Fasola G; Cascinu S; Scartozzi M
    Curr Drug Targets; 2014; 15(13):1225-30. PubMed ID: 25382208
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer.
    Dunne PD; McArt DG; Blayney JK; Kalimutho M; Greer S; Wang T; Srivastava S; Ong CW; Arthur K; Loughrey M; Redmond K; Longley DB; Salto-Tellez M; Johnston PG; Van Schaeybroeck S
    Clin Cancer Res; 2014 Jan; 20(1):164-75. PubMed ID: 24170546
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Association of a common genetic variant of the IGF-1 gene with event-free survival in patients with her2-positive breast cancer.
    Muendlein A; Lang AH; Geller-Rhomberg S; Winder T; Gasser K; Drexel H; Decker T; Mueller-Holzner E; Chamson M; Marth C; Hubalek M
    J Cancer Res Clin Oncol; 2013 Mar; 139(3):491-8. PubMed ID: 23180020
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Breast cancer expression of YKL-40 correlates with tumour grade, poor differentiation, and other cancer markers.
    Shao R; Cao QJ; Arenas RB; Bigelow C; Bentley B; Yan W
    Br J Cancer; 2011 Oct; 105(8):1203-9. PubMed ID: 21934681
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. her2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer.
    Al-Kuraya K; Novotny H; Bavi P; Siraj AK; Uddin S; Ezzat A; Sanea NA; Al-Dayel F; Al-Mana H; Sheikh SS; Mirlacher M; Tapia C; Simon R; Sauter G; Terracciano L; Tornillo L
    J Clin Pathol; 2007 Jul; 60(7):768-72. PubMed ID: 16882699
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Tumor cell dissemination in colon cancer does not predict extrahepatic recurrence in patients undergoing surgery for hepatic metastases.
    Schoppmeyer K; Frühauf N; Oldhafer K; Seeber S; Kasimir-Bauer S
    Oncol Rep; 2006 Feb; 15(2):449-54. PubMed ID: 16391868
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Current status of small-molecule tyrosine kinase inhibitors targeting epidermal growth factor receptor in colorectal cancer.
    Kuo T; Fisher GA
    Clin Colorectal Cancer; 2005 Nov; 5 Suppl 2():S62-70. PubMed ID: 16336751
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. COX-2, c-KIT and her-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies?
    Raspollini MR; Susini T; Amunni G; Paglierani M; Taddei A; Marchionni M; Scarselli G; Taddei GL
    Gynecol Oncol; 2005 Jan; 96(1):159-67. PubMed ID: 15589595
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. The expression and prognostic significance of her-2 in colorectal cancer and its relationship with clinicopathological parameters.
    Essapen S; Thomas H; Green M; De Vries C; Cook MG; Marks C; Topham C; Modjtahedi H
    Int J Oncol; 2004 Feb; 24(2):241-8. PubMed ID: 14719098
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Relevance of biologic markers in colorectal carcinoma: a comparative study of a broad panel.
    Barozzi C; Ravaioli M; D'Errico A; Grazi GL; Poggioli G; Cavrini G; Mazziotti A; Grigioni WF
    Cancer; 2002 Feb; 94(3):647-57. PubMed ID: 11857296
    [TBL] [Abstract] [Full Text] [Related]  

    of 1.